Extraskeletal myxoid chondrosarcoma: A retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy

Cancer

Volumn 113, Issue 12, 2008, Pages 3364-3371

  Drilon, Alex D ^a   Popat, Sanjay ^b   Bhuchar, Gauri ^a   D'Adamo, David R ^a   Keohan, Mary Louise ^a   Fisher, Cyril ^b   Antonescu, Cristina R ^a   Singer, Samuel ^a   Brennan, Murray F ^a   Judson, Ian ^b   Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Chromosomal translocation; Extraskeletal myxoid chondrosarcoma; Retrospective analysis; Soft tissue sarcoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; METHOTREXATE; PREDNISONE; SORAFENIB; THALIDOMIDE; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHONDROSARCOMA; DISEASE COURSE; DRUG RESPONSE; EXTRASKELETAL MYXOID CHONDROSARCOMA; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; METASTASIS; MYXOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEX RATIO; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHONDROSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 57649115552     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23978     Document Type: Article

References (39)

1. Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol. 2004;16:342-354.
2. Hirabayashi Y, Ishida T, Yoshida MA, et al. Translocation (9;22)(q22;q12). A recurrent chromosome abnormality in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet. 1995;81:33-37.
3. Stenman G, Andersson H, Mandahl N, Meis-Kindblom JM, Kindblom LG. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer. 1995;62:398-402.
4. Panagopoulos I, Mertens F, Isaksson M, et al. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer. 2002;35:340-352.
5. Filion C, Labelle Y. The oncogenic fusion protein EWS/NOR-1 induces transformation of CFK2 chondrogenic cells. Exp Cell Res. 2004;297:585-592.
6. Oliveira AM, Nascimento AG. Phenotypic plasticity and prognostic factors in extraskeletal myxoid chondrosarcoma. Adv Anat Pathol. 2000;7:73-78.
7. Aigner T, Oliveira AM, Nascimento AG. Extraskeletal myxoid chondrosarcomas do not show a chondrocytic phenotype. Mod Pathol. 2004;17:214-221.
8. Goh YW, Spagnolo DV, Platten M, et al. Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology. 2001;39:514-524.
9. Hisaoka M, Okamoto S, Koyama S, et al. Microtubule-associated protein-2 and class III beta-tubulin are expressed in extraskeletal myxoid chondrosarcoma. Mod Pathol. 2003;16:453-459.
10. McGrory JE, Rock MG, Nascimento AG, Oliveira AM. Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res. 2001;(382):185-190.
11. Saleh G, Evans HL, Ro JY, Ayala AG. Extraskeletal myxoid chondrosarcoma. A clinicopathologic study of ten patients with long-term follow-up. Cancer. 1992;70:2827-2830.
12. Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG. Extraskeletal myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol. 1999;23:636-650.
13. Kawaguchi S, Wada T, Nagoya S, et al. Extraskeletal myxoid chondrosarcoma: a multi-institutional study of 42 cases in Japan. Cancer. 2003;97:1285-1292.
14. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res. 2003;(415):4-18.
15. Patel SR, Burgess MA, Papadopoulos NE, Linke KA, Benjamin RS. Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol. 1995;18:161-163.
16. Hisaoka M, Ishida T, Imamura T, Hashimoto H. TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer. 2004;40:325-328.
17. Maltais A, Filion C, Labelle Y. The AF2 domain of the orphan nuclear receptor TEC is essential for the transcriptional activity of the oncogenic fusion protein EWS/TEC. Cancer Lett. 2002;183:87-94.
18. Labelle Y, Bussieres J, Courjal F, Goldring MB. The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. Oncogene. 1999;18:3303-3308.
19. Attwooll C, Oddi S, Cartwright P, et al. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J Biol Chem. 2005;280:1199-1208.
20. Kim S, Lee J, Kim J. Regulation of oncogenic transcription factor hTAF(II)68-TEC activity by human glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Biochem J. 2007;404:197-206.
21. Attwooll C, Tariq M, Harris M, Coyne JD, Telford N, Varley JM. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene. 1999;18:7599-7601.
22. Bjerkehagen B, Dietrich C, Reed W, et al. Extraskeletal myxoid chondrosarcoma: multimodal diagnosis and identification of a new cytogenetic subgroup characterized by t(9;17)(q22;q11). Virchows Arch. 1999;435:524-530.
23. Sjogren H, Wedell B, Meis-Kindblom JM, Kindblom LG, Stenman G. Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res. 2000;60:6832-6835.
24. Gan TI, Rowen L, Nesbitt R, et al. Genomic organization of human TCF12 gene and spliced mRNA variants producing isoforms of transcription factor HTF4. Cytogenet Genome Res. 2002;98:245-248.
25. Ohkura N, Yaguchi H, Tsukada T, Yamaguchi K. The EWS/ NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing. J Biol Chem. 2002;277:535-543.
26. Okamoto S, Hisaoka M, Ishida T, et al. Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases. Hum Pathol. 2001; 32:1116-1124.
27. Oliveira AM, Sebo TJ, McGrory JE, Gaffey TA, Rock MG, Nascimento AG. Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases. Mod Pathol. 2000;13:900-908.
28. Tsuneyoshi M, Enjoji M, Iwasaki H, Shinohara N. Extraskeletal myxoid chondrosarcoma-a clinicopathologic and electron microscopic study. Acta Pathol Jpn. 1981;31:439-447.
29. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350-362.
30. Rubinger M, Plenderleith IH, Lertzman M, Worth AJ. Metastatic extraskeletal myxoid chondrosarcoma. Successful therapy with interferon alfa-2b. Chest. 1995;108:281-282.
31. Hisaoka M, Hashimoto H. Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. Pathol Int. 2005;55:453-463.
32. Poulin H, Filion C, Ladanyi M, Labelle Y. Serum- and glucocorticoid- regulated kinase 1 (SGK1) induction by the EWS/NOR1(NR4A3) fusion protein. Biochem Biophys Res Commun. 2006;346:306-313.
33. Kagaya S, Ohkura N, Tsukada T, et al. Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily. Biol Pharm Bull. 2005;28:1603-1607.
34. Hisaoka M, Okamoto S, Yokoyama K, Hashimoto H. Coexpression of NOR1 and SIX3 proteins in extraskeletal myxoid chondrosarcomas without detectable NR4A3 fusion genes. Cancer Genet Cytogenet. 2004;152:101-107.
35. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res. 2001;7:2076-2084.
36. Subramanian S, West RB, Marinelli RJ, et al. The gene expression profile of extraskeletal myxoid chondrosarcoma. J Pathol. 2005;206:433-444.
37. Koyama H, Boueres JK, Han W, et al. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists. Bioorg Med Chem Lett. 2003;13:1801-1804.
38. Sponsors and Collaborators: SARC (Sarcoma Alliance for Research through Collaboration) and AOI Pharma, Inc. Protocol title: A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas. Available at: http://www. Clinicaltrials.gov. Clinical Trial Identifier NCT00401388, vol. 2008, 2008. Accessed on October 6, 2008.
39. Sponsors and Collaborators: SARC (Sarcoma Alliance for Research through Collaboration) and Hoffmann-La Roche, Inc. Protocol title: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma. Available at: http://www.Clinicaltrials.gov. Clinical Trial Identifier NCT00642941, vol. 2008, 2008. Accessed on October 6, 2008.